The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Prospective Clinical Research Of Radiation Response To High-dose Radiotherapy In Lung Tumours And Surrounding Normal Tissue Using Functional Imaging Biomarker Assessments
Funder
National Health and Medical Research Council
Funding Amount
$120,275.00
Summary
Radiotherapy is a potentially curative treatment for cancers of the lung. To improve outcomes, modern research efforts have focussed on radiotherapy dose escalation. However a major limitation to dose escalation is the associated toxicity to the lung. At present, the mechanisms of lung toxicity are incompletely understood. This research will investigate biomarkers of radiation response in patients receiving high-dose radiotherapy to the lung by using state-of-the-art scanning techniques.
Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and l ....Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and lead to a personalized treatment of rectal cancer.Read moreRead less
Overcoming Radiation Resistance In Glioblastoma With Novel Metabolic Modulations
Funder
National Health and Medical Research Council
Funding Amount
$62,554.00
Summary
Aim 1 is to document the pathological, surgical, radiotherapy and chemotherapy patterns of care in the Australian setting using the AGOG (Australian Genomics and Clinical Outcomes of Glioma) database. The second aim to develop non-invasive imaging biomarkers which can be used to monitor treatment efficacy. The third aim is to improve outcomes using drug and radiation combination therapy. in the treatment of high grade gliomas.